Lupin receives FDA approval for generic Clobex Spray, 0.05%
29 March 2018 | News
It is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older
Pharma major Lupin announced that it has received final approval for its Clobetasol Propionate Spray, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Galderma Laboratories, L.P.’s Clobex® Spray, 0.05%.
Lupin’s Clobetasol Propionate Spray, 0.05% is the generic equivalent of Galderma Laboratories, L.P.’s Clobex® Spray, 0.05%.
It is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.
Clobetasol Propionate Spray, 0.05% had annual sales of approximately USD 30.5 million in the US (IQVIA MAT January 2018).
